![]() There are some other positives for Novavax, as the company could see some potential upside from its promising NanoFlu vaccine, which it has been looking to combine with its Covid-19 shot, and also from its adjuvant called Matrix-M, which is used to enhance the immune response of vaccines. While Novavax recently said that its vaccine produces an immune response to the Omicron variant, based on initial data, it probably doesn’t mean too much at this point, as the current Covid-19 wave will likely be over by the time the company’s shot is approved in the U.S. Now Novavax stock has been particularly badly hit, given that it has yet to deliver its vaccine commercially in the U.S., with regulatory approval only looking likely in the coming months. For instance, Moderna stock and BioNTech stock are down by almost 20% and 27% year-to-date, respectively. Moreover, therapeutic options for Covid-19 are improving, with the new virus variant also appearing to result in a much lower rate of severe disease, potentially dampening the incentive for people to get booster doses. ![]() With the big initial inoculation drive of the early pandemic now done, it’s looking likely that vaccine demand will remain flat or possibly decline in 2022. Covid-19 daily cases have been surging (over 800,000 over the last week), investors have generally been souring on vaccine stocks for a couple of reasons. Covid-19 vaccine developer Novavax’s stock (NASDAQ: NVAX) has declined by almost 31% thus far in 2022, considerably underperforming the S&P 500, which is down by about -4.5% over the same period.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |